Get the Stockscreener App
1.89
12.50%
0.21
Inhibikase Therapeutics Inc stock is traded at $1.89, with a volume of 218.89K.
It is up +12.50% in the last 24 hours and down -2.07% over the past month.
Inhibikase Therapeutics Inc is a a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease (PD), Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases. Its multi-therapeutic pipeline has a primary focus on neurodegeneration and its program utilizing Risvodetinib (also known as IkT-148009), a selective inhibitor of the non-receptor Abelson Tyrosine Kinases, targets the treatment of Parkinson's disease inside and outside the brain as well as other diseases that arise from Abelson Tyrosine Kinases.
See More
Previous Close:
$1.68
Open:
$1.7
24h Volume:
218.89K
Relative Volume:
0.92
Market Cap:
$140.51M
Revenue:
-
Net Income/Loss:
$-19.57M
P/E Ratio:
-0.6038
EPS:
-3.13
Net Cash Flow:
$-17.24M
1W Performance:
+8.00%
1M Performance:
-2.07%
6M Performance:
-36.36%
1Y Performance:
+37.96%
1-Day Range:
$1.69
$1.90
1-Week Range:
$1.56
$1.90
52-Week Range:
$1.12
$4.20
Inhibikase Therapeutics Inc Stock (IKT) Company Profile
Name
Inhibikase Therapeutics Inc
Sector
Industry
Phone
(302) 295-3800
Address
1000 N. WEST STREET, SUITE 1200, WILMINGTON
Compare IKT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IKT
Inhibikase Therapeutics Inc
|
1.89 | 127.87M | 0 | -19.57M | -17.24M | -3.13 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Inhibikase Therapeutics Inc Stock (IKT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-12-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
Inhibikase Therapeutics Inc Stock (IKT) Latest News
Real time breakdown of Inhibikase Therapeutics Inc. stock performanceJuly 2025 Outlook & Scalable Portfolio Growth Methods - Newser
Inhibikase Therapeutics Inc. Building a Base Near SupportWeekly Investment Summary & Real-Time Stock Movement Alerts - thegnnews.com
What data driven models say about Inhibikase Therapeutics Inc.’s futureGlobal Markets & Risk Managed Investment Signals - Newser
Live market analysis of Inhibikase Therapeutics Inc.July 2025 Decliners & Verified Momentum Stock Ideas - Newser
Visual analytics tools that track Inhibikase Therapeutics Inc. performanceJuly 2025 Sector Moves & Real-Time Volume Surge Alerts - Newser
What does recent volatility data suggest for Inhibikase Therapeutics Inc.2025 Market Trends & Weekly Market Pulse Updates - Newser
How high can Inhibikase Therapeutics Inc. stock goJuly 2025 Outlook & AI Enhanced Trading Signals - Newser
Applying Elliott Wave Theory to Inhibikase Therapeutics Inc.Buy Signal & Fast Gain Swing Alerts - Newser
Using Python tools to backtest Inhibikase Therapeutics Inc. strategies2025 Short Interest & High Return Trade Guides - Newser
What moving averages say about Inhibikase Therapeutics Inc.July 2025 Summary & Long-Term Growth Portfolio Plans - Newser
Inhibikase Therapeutics Strengthens Leadership Team with Appointment of Timothy Pigot as Chief Commercial and Strategy Officer | IKT Stock News - GuruFocus
Inhibikase's Strategic Hire of Timothy Pigot: A Catalyst for IKT-001's Commercial Success in PAH - AInvest
Inhibikase Therapeutics Strengthens Leadership Team with Appointment of Timothy Pigot as Chief Commercial and Strategy Officer - Yahoo Finance
Is it time to cut losses on Inhibikase Therapeutics Inc.Stock Surge & Momentum Based Trading Signals - Newser
Inhibikase Therapeutics Reports Q2 2025 Financials and Progress - MSN
Chart based analysis of Inhibikase Therapeutics Inc. trendsTreasury Yields & High Accuracy Investment Entry Signals - Newser
Visual trend scoring systems applied to Inhibikase Therapeutics Inc.Weekly Profit Summary & Verified Entry Point Signals - Newser
Inhibikase Therapeutics Inc. Breaks Below Key Support LevelEntry Point & Weekly Stock Performance Updates - metal.it
Key metrics from Inhibikase Therapeutics Inc.’s quarterly dataMarket Activity Recap & Entry Point Confirmation Signals - Newser
Risk vs reward if holding onto Inhibikase Therapeutics Inc.Quarterly Performance Summary & Daily Market Momentum Tracking - Newser
Trend Dashboard Flags Inhibikase Therapeutics Inc. As Potential Swing TradeJuly 2025 Pullbacks & Fast Gaining Stock Strategy Reports - sundaytimes.kr
Strategies to average down on Inhibikase Therapeutics Inc.Analyst Upgrade & Weekly High Conviction Ideas - Newser
How institutional ownership impacts Inhibikase Therapeutics Inc. stockJuly 2025 News Drivers & Real-Time Buy Signal Alerts - Newser
New Product Launches: Will They Boost Inhibikase Therapeutics Inc. Stock in 2025Market Movement Recap & Risk Controlled Swing Trade Alerts - Newser
Inhibikase Therapeutics: Is the GAAP EPS Loss a Short-Term Hurdle or a Warning Sign? - AInvest
Inhibikase Posts Wider Loss in Q2 - AOL.com
Trend Reversal Possible in Inhibikase Therapeutics Inc. Charts IndicateJuly 2025 Closing Moves & Verified Swing Trading Watchlists - 선데이타임즈
Inhibikase Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Inhibikase Therapeutics Reports Q2 2025 Financial Results - TipRanks
Inhibikase Therapeutics Announces Second Quarter 2025 Financial Results and Highlights Recent Activity | IKT Stock News - GuruFocus
Inhibikase Therapeutics, Inc. SEC 10-Q Report - TradingView
Inhibikase Therapeutics Announces Second Quarter 2025 Financial Results and Highlights Recent Activity - The Manila Times
Inhibikase Therapeutics Reports Q2 2025 Financial Results and Advances IKT-001 Clinical Trial for Pulmonary Arterial Hypertension - Quiver Quantitative
Inhibikase's PAH Drug Advances to Phase 2b Trial With Promising Efficacy Target in Pulmonary Disease - Stock Titan
What makes Inhibikase Therapeutics Inc. stock price move sharplyJuly 2025 Patterns & Reliable Momentum Entry Alerts - Newser
Inhibikase Therapeutics Inc Stock (IKT) Financials Data
Revenue
Net Income
Cash Flow
EPS
Inhibikase Therapeutics Inc Stock (IKT) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Kush Arvind | Director |
Oct 21 '24 |
Buy |
1.37 |
145,000 |
198,650 |
145,000 |
| Munshi Amit | Director |
Oct 21 '24 |
Buy |
1.37 |
365,000 |
500,050 |
365,000 |
0.94%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):